News brief­ing: PhI­II Alzheimer's play draws an­oth­er $33M+; Ar­ran­ta un­veils $100M+ mi­cro­bio­me man­u­fac­tur­ing site

More mon­ey is flow­ing to­wards the dis­as­ter-prone yet high­ly sought af­ter quest for an Alzheimer’s dis­ease treat­ment. To­day, it is AZTher­a­pies’s turn to rake it in.

The Boston-based biotech has closed $33.6 mil­lion in Se­ries C-1 fund­ing, which comes on the heels of a $37.5 mil­lion Se­ries C.

“This ad­di­tion­al fund­ing po­si­tions us ex­treme­ly well as we dri­ve to­wards com­ple­tion of our Phase 3 COG­NITE tri­al in Alzheimer’s dis­ease lat­er this year, with da­ta read­out ex­pect­ed in ear­ly 2021,” CEO David El­maleh said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER